| Primary information |
|---|
| ID | antitb_1440, |
| Name | 25809751 |
| N-Terminal modification | A2-TB10.4 |
| C-Terminal Modification | AMLGHAGDM |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | None |
| Chirality | Linear |
| Nature | 9 |
| Source | L |
| Species | Protein derived |
| Strain | MTB derived protein TB10.4 |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis Rv |
| Sequence | 2104 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment |
| Combination Therapy | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. |
| Other activities | CD8+ T-cell |
| PMID | NA |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |